Boehringer Ingelheim, Evotec and bioMérieux forms JV Aurobac to fight antimicrobial resistance
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
People in India are still wary of organ transplants. So, there is an urgent need of increased public awareness.
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
The settlement and dismissal resolves all claims between the parties
Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.
The Congress was held on June, 20-21, 2022 in Berlin, Germany
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
Most recently, she served as chief human resources officer at Vyripharm Enterprises.
Subscribe To Our Newsletter & Stay Updated